Christian Dreger - PAREXEL International President

Dr. Christian Dreger, Ph.D., was appointed as Senior Vice President Parexel Access and Parexel Consulting of the Company. Dr. Dreger joins PAREXEL from Biogen where he served as Vice President and Head of Global Commercial Operations, Biosimilars, in Zug, Switzerland. Dr. Dreger has also held international commercial and sales positions of increasing responsibility with billiondollar PL and performance management responsibilities at Cubist Pharmaceuticals, AstraZeneca, ScheringPlough, and Roche Pharmaceuticals and Diagnostics. He started his career as a consultant with McKinsey Co. in Germany
  President Since 2016  MBA    
781 487-9900
Dreger holds an MBA and a Ph.D. from the University of Mannheim in Germany and St. Gallen, Switzerland, and an Executive MBA from Northwestern University Kellogg Graduate School of Management. He also holds an LLB from the University of Hagen in Germany and is a certified pharmaceutical advisor and board director from INSEAD, Fontainebleau, France.

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Roman TrawickiZoetis
John WesolowskiPerrigo Company Plc
Michael StewartPerrigo Company Plc
Andrew FentonZoetis
Michael PartridgeVertex Pharmaceuticals Incorpor
Sripada ChandrasekharDr Reddys Laboratories Ltd
John HendricksonPerrigo Company Plc
Scott JamisonPerrigo Company Plc
Heidi ChenZoetis
Louis YuPerrigo Company Plc
James MichaudPerrigo Company Plc
Catherine KnuppZoetis
Roxanne LaganoZoetis
Sandra BeatyZoetis
Raghav ChariDr Reddys Laboratories Ltd
Ganadhish KamatDr Reddys Laboratories Ltd
J RamachandranDr Reddys Laboratories Ltd
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Kimberly WhiteVertex Pharmaceuticals Incorpor
Jay MarkowitzRegeneron Pharmaceuticals

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Correlation Analysis Now


Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.